Biomea Fusion reports new preclinical data on icovamenib-semaglutide study

Biomea Fusion (BMEA) announce compelling results from in vivo studies of icovamenib in combination with semaglutide. Highlights of the Study: Superior Glycemic Control: A 60% reduction in fasting blood glucose level was observed with combination therapy compared to semaglutide alone. A 50% reduction in area under the curve (AUC) was observed during the Oral Glucose Tolerance Test with combination therapy versus semaglutide alone, indicating improved glucose metabolism. Improvements in HbA1c: HbA1c reduction on Day 28 was greater with the combination therapy compared to semaglutide alone. Reduced Insulin Resistance and Improvements in Beta Cell Function: Insulin resistance as measured by HOMA-IR was reduced by 75% with combination therapy compared to semaglutide alone. Combination treatment also improved beta-cell function as measured by HOMA-B. Weight Loss and Muscle Mass Improvements: Combination therapy reduced body weight by 11.5% and fat mass by 29.5% compared to semaglutide alone. A 43% increase in lean mass compared to semaglutide alone was also observed with combination therapy. We believe these results underscore the combination’s unique ability to reduce fat mass while preserving and enhancing lean muscle mass. Validated Safety: Icovamenib in combination with semaglutide was well tolerated across multiple time points.